In order to obtain trustable blood and blood products in blood banks, screening for hepatitis B virus DNA (HBV DNA) with nucleic acid amplification technology was tested for its possisle application in Turkey. The blood samples taken from 3000 donors whose screening test results were negative were included in the study. With the serum samples 300 pools were prepared, and the pooled sera were studied by using HBV RT-PCR tool. Of the 170 donation serum samples within 17 falcons with positive HBV DNA, five samples were detected to have positive HBV DNA. Donors with positive HBV DNA RT-PZR were recontacted and new serum samples were taken. None of these samples were positive for HBV. Using the RT-PCR method, the artifical positivity ratio of HBV DNA was found as 0.16%, concluding that this artificial positivity was a result of cross contamination. Due to the low HBV seroprevalance, the current number of donors' sera seems to be insufficient. In order to test further the applicability of the NAT in blood banks in Turkey, studies with more sera from different regions of the country are needed.